Stabilized Amyloid Oligomers and Applications for Alzheimer’s Research and Treatment

Brief Description

An innovative approach to advancing Alzheimer's disease research, detection, and treatment through the development of synthetic amyloid peptides and oligomers.

Full Description

This technology encompasses the synthesis of synthetic amyloid peptides and oligomers that mimic the amyloid-beta structures involved in Alzheimer's disease (AD). It includes methods for creating stable, soluble oligomers and specific antibodies against these oligomers, aiming to enhance understanding, detection, and therapeutic intervention in AD. The peptides are designed to replicate various forms of amyloid-beta, including those with mutations linked to familial Alzheimer's disease, and can form structures such as trimers through covalent links and disulfide bridges. Additionally, the technology outlines methods for producing antibodies with high affinity for soluble amyloid oligomers, potentially leading to novel diagnostic and therapeutic tools.

Suggested uses

• Pharmaceutical development for Alzheimer's disease therapeutics. 
• Clinical diagnostics for early detection of Alzheimer's disease. 
• Academic and pharmaceutical research into the pathogenesis of Alzheimer's disease. 
• Production of research-grade antibodies for biomedical research.

Advantages

• Facilitates advanced Alzheimer's disease research by providing synthetic models of amyloid oligomers. 
• Supports the development of targeted therapies and diagnostics. 
• Enables the production of high-affinity antibodies against soluble amyloid oligomers. 
• Offers potential for understanding the role of amyloid oligomers in Alzheimer's disease progression. 
• Includes peptides with mutations corresponding to familial Alzheimer's disease for broader research applications.

Patent Status